跳至主要内容
临床试验/NCT02428699
NCT02428699已完成不适用

Comparison of Plasma Levels of n-3 Fatty Acids After Ingestion of an Emulsified Cod Liver Oil Product and a Non Emulsified Cod Liver Oil Product

GlaxoSmithKline2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2015年5月20日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
50
试验地点
2
主要终点
Incremental Area Under the Curve to 24 Hours (h) (iAUC0-24h) of the Sum of Plasma Total and Free n-3 Fatty Acids (Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA)

研究概览

简要总结

This study is designed to compare the incremental area under the curve from 0 to 24h (iAUC0-24h) of plasma levels of n-3 fatty acids (sum of total and free eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) after ingestion of an emulsified product and a non-emulsified reference control of free flowing cod liver oil at the lowest appropriate dose that is practically acceptable, and as near as possible to the test products' recommended daily dose.

详细描述

Many dietary lipids are in the form of triglycerides, ethyl esters or phospholipids. During digestion these lipids are subject to hydrolysis, in particular by pancreatic triglyceride lipase. To facilitate the action of the enzyme, lipids are emulsified by the action of bile salts. By increasing the surface area of the fat globules, emulsification increases access to the lipids by pancreatic triglyceride lipase. This study is designed to compare iAUC0-24h of plasma levels of n-3 fatty acids (sum of total and free EPA and DHA) after ingestion of an emulsified product and a non-emulsified reference control of free flowing cod liver oil at the lowest appropriate dose that is practically acceptable, and as near as possible to the test products' recommended daily dose.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy volunteers aged 18 to 45 years (both inclusive)
  • Body mass index (BMI) of 18.5-29.9 kg/m2 inclusive

排除标准

  • Pregnant or lactating women
  • Allergy/intolerance to any study material
  • Current or recurrent disease, within 12 months of screening that could affect the metabolism of drug
  • Participants who have taken any drug known to induce or inhibit hepatic drug metabolism in 30 days prior to screening
  • Positive serum Hepatitis B surface antigen, Hepatitis C antibodies or Human Immunodeficiency Virus (HIV), alcohol or drug abuse
  • Smokers taking >5 cigarettes/day; prior or current use of any other nicotine containing product
  • Blood donated within 3 months of screening
  • Consumed n-3 rich food or beverage or n-3 fortified food or beverage within 72h prior to each study session

结局指标

主要结局

Incremental Area Under the Curve to 24 Hours (h) (iAUC0-24h) of the Sum of Plasma Total and Free n-3 Fatty Acids (Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA)

时间窗: Baseline and up to Day 2

The AUC was calculated using the trapezoidal method and using nominal time points from 0, 2, 4, 6, 8, 10, 12 and 24 h respectively. The AUC was divided by the total duration to represent a weighted mean incremental change over time. Higher values of AUC demonstrate better rate of absorption over time than lower values.

次要结局

  • Maximum Concentration (Cmax) of Sum of Total and Free DHA and EPA(Baseline and up to Day 2)
  • Tmax of Sum of Total and Free DHA(Baseline and up to Day 2)
  • Tmax of Sum of Total and Free EPA(Baseline and up to Day 2)
  • iAUC0-24h of Sum of Total and Free DHA(Baseline and up to Day 2)
  • Cmax of Sum of Total and Free DHA(Baseline and up to Day 2)
  • iAUC0-24h of Sum of Total and Free EPA(Baseline and up to Day 2)
  • iAUC0-10h of Sum of Total and Free DHA and EPA(Upto 10 h)
  • Cmax of Sum of Total and Free EPA(Baseline and up to Day 2)
  • iAUC0-10h of Sum of Total and Free DHA(Upto 10 h)
  • iAUC0-10h of Sum of Total and Free EPA(Upto 10 h)
  • Time to Maximum Concentration (Tmax) of Sum of Total and Free DHA and EPA(Baseline and up to Day 2)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验